Gain Therapeutics Inc (NASDAQ:GANX) — Market Cap & Net Worth
Market Cap & Net Worth: Gain Therapeutics Inc (GANX)
Gain Therapeutics Inc (NASDAQ:GANX) has a market capitalization of $72.31 Million ($72.31 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20452 globally and #4412 in its home market, demonstrating a -0.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gain Therapeutics Inc's stock price $1.88 by its total outstanding shares 38462085 (38.46 Million). Analyse GANX cash generation efficiency to see how efficiently the company converts income to cash.
Gain Therapeutics Inc Market Cap History: 2021 to 2026
Gain Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $208.85 Million to $72.31 Million (-29.41% CAGR).
Index Memberships
Gain Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #586 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1981 of 3165 |
Weight: Gain Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Gain Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gain Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2275.80x
Gain Therapeutics Inc's market cap is 2275.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $208.85 Million | $133.93K | -$13.89 Million | 1559.41x | N/A |
| 2022 | $120.39 Million | $132.64K | -$17.59 Million | 907.62x | N/A |
| 2023 | $125.58 Million | $55.18K | -$22.27 Million | 2275.80x | N/A |
Competitor Companies of GANX by Market Capitalization
Companies near Gain Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Gain Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Gain Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Gain Therapeutics Inc's market cap moved from $208.85 Million to $ 72.31 Million, with a yearly change of -29.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $72.31 Million | -41.61% |
| 2025 | $123.85 Million | +49.07% |
| 2024 | $83.08 Million | -33.84% |
| 2023 | $125.58 Million | +4.31% |
| 2022 | $120.39 Million | -42.36% |
| 2021 | $208.85 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Gain Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $72.31 Million USD |
| MoneyControl | $72.31 Million USD |
| MarketWatch | $72.31 Million USD |
| marketcap.company | $72.31 Million USD |
| Reuters | $72.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the … Read more